Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy

Neurology

Volumn 87, Issue 20, 2016, Pages 2123-2131

  Griggs, Robert C ^a   Miller, J Phillip ^b   Greenberg, Cheryl R ^c   Fehlings, Darcy L ^d   Pestronk, Alan ^b   Mendell, Jerry R ^a   Moxley, Richard T ^a   King, Wendy ^f   Kissel, John T ^f   Cwik, Valerie ^g   Vanasse, Michel ^h   Florence, Julaine M ^b   Pandya, Shree ^a   Dubow, Jordan S ⁱ   Meyer, James M ^e,i  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e NATIONWIDE CHILDREN S HOSPITAL   (United States)

^f THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^g Muscular Dystrophy Association   (United States)

^h UNIVERSITY OF MONTREAL   (Canada)

ⁱ Marathon Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; DEFLAZACORT; PLACEBO; PREDNISONE; ANTIINFLAMMATORY AGENT; PREGNANE DERIVATIVE;

ABNORMAL BEHAVIOR; ADOLESCENT; AGGRESSION; ARTICLE; CATARACT; CHILD; CLIMBING; CONSTIPATION; COUGHING; CREATINE KINASE BLOOD LEVEL; CUSHINGOID SYNDROME; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DUCHENNE MUSCULAR DYSTROPHY; ERYTHEMA; FEMALE; FEVER; HEADACHE; HIRSUTISM; HUMAN; INCREASED APPETITE; INFLUENZA; IRRITABILITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MOOD CHANGE; MOTOR PERFORMANCE; MULTICENTER STUDY; MUSCLE STRENGTH; OBESITY; PHASE 3 CLINICAL TRIAL; POLLAKISURIA; PRIORITY JOURNAL; PSYCHOSIS; RHINOPHARYNGITIS; SIDE EFFECT; STANDING; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECTS; LEAST SQUARE ANALYSIS; MOTOR ACTIVITY; MUSCULAR DYSTROPHY, DUCHENNE; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MOTOR ACTIVITY; MUSCLE STRENGTH; MUSCULAR DYSTROPHY, DUCHENNE; PREDNISONE; PREGNENEDIONES; TREATMENT OUTCOME;

EID: 84995592213     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003217     Document Type: Article

References (24)

1. Mendell JR, Shilling C, Leslie ND, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 2012;71:304-313.
2. Moxley RT III, Ashwal S, Pandya S, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005;64:13-20.
3. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77-93.
4. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010;9:177-189.
5. Griggs RC, Moxley RT III, Mendell JR, et al. Prednisone in Duchenne dystrophy: a randomized, controlled trial defining the time course and dose response: clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 1991;48:383-388.
6. Fenichel GM, Mendell JR, Moxley RT, et al. A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol 1991;48:575-579.
7. Griggs RC, Moxley RT, Mendell JR, et al. Duchenne dystrophy: randomized controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993; 43:520-527.
8. Nathanson G, Winters G, Testa E. Steroids possessing nitrogen atoms: 3: synthesis of new highly active corticoids [17-alpha, 16-alpha-d]oxazolino steroids. J Med Chem 1967;10:799-802.
9. Bonifati MD, Ruzza G, Bonometto P, et al. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 2000;23:1344-1347.
10. Reitter B. Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain Dev 1995(17 Suppl):39-43.
11. Brooke MH. A randomized trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology 1996;46:A476.
12. Mendell JR, Moxley RT, Griggs RC, et al. Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989;320:1592-1597.
13. Mesa LE, Dubrovsky AL, Corderi J, Marco P, Flores D. Steroids in Duchenne muscular dystrophy-deflazacort trial. Neuromuscul Disord 1991;1:261-266.
14. Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006;16:249-255.
15. Houde S, Filiatrault M, Fournier A, et al. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatr Neurol 2008;38:200-206.
16. Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, Costa C. Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle Nerve 1994;17:386-391.
17. Lund B, Egmose C, Jorgensen S, Krogsgaard MR. Establishment of the relative antiiflammatory potency of deflazacort and prednisone in polymyalgia rheumatica. Calcif Tissue Int 1987;41:316-320.
18. Bello L, Gordish-Dressman H, Morgenroth LP, et al. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne natural history study. Neurology 2015; 85:1048-1055.
19. Bianchi ML, Mazzanti A, Galbiati E, et al. Bone mineral density and bone metabolism in Duchenne muscular dystrophy. Osteoporos Int 2003;14:761-767.
20. Mah JK, Hu F, McDonald CM. Short stature prolonged ambulation in boys with Duchenne muscular dystrophy. Can J Neurol Sci 2012;39:S13.
21. Schara U, Mortier W. Long-term steroid therapy in Duchenne muscular dystrophy: positive results versus side effects. J Clin Neuromuscul Dis 2001;2:179-183.
22. Griggs RC, Bushby K. Finding the optimum regimen for Duchenne muscular dystrophy (FOR-DMD). In: Clinical-Trials. gov. Bethesda, MD: National Library of Medicine; 2000. Available at: https://clinicaltrials. gov/ct2/show/ NCT01603407?term5for-dmd&rank51: NCT01603407. Accessed January 26, 2016.
23. Escolar DM, Hache LP, Clemens PR, et al. Randomized trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011;77:444-452.
24. Matthews DJ, James KA, Miller LA, et al. MDSTARnet: use of corticosteroids in a population-based cohort of boys with Duchenne and Becker muscular dystrophy. J Child Neurol 2010;25:1319-1324